People: Acura Pharmaceuticals Inc (ACUR.OQ)

ACUR.OQ on NASDAQ Stock Exchange Capital Market

1.98USD
1 Aug 2013
Price Change (% chg)

$-0.06 (-2.94%)
Prev Close
$2.04
Open
$1.99
Day's High
$2.01
Day's Low
$1.90
Volume
57,968
Avg. Vol
92,365
52-wk High
$4.49
52-wk Low
$1.06

Search Stocks

Summary

Name Age Since Current Position

Robert Jones

54 2011 President, Chief Executive Officer, Director

Peter Clemens

60 2004 Chief Financial Officer, Senior Vice President, Secretary

Robert Seiser

49 2004 Vice President, Corporate Controller and Treasurer

J. Bradley Rivet

59 2011 Vice President - Marketing

Albert Brzeczko

56 2009 Vice President -Technical Affairs

James Emigh

57 2011 Vice President - Corporate Development

George Ross

71 2008 Independent Director

William Skelly

62 2000 Independent Director

Immanuel Thangaraj

42 2002 Independent Director

Bruce Wesson

70 1998 Independent Director

Biographies

Name Description

Robert Jones

Mr. Robert B. Jones is President, Chief Executive Officer, Director of Acura Pharmaceuticals, Inc., since July 7, 2011. He has been President and Chief Executive Officer since July 7, 2011. From April 2011 through July 6, 2011, Mr. Jones was Interim President and Chief Executive Officer. Mr. Jones was Senior Vice President and Chief Operating Officer from April 2008 to April 2011. From May, 2003 to March, 2008, Mr. Jones served first as the Vice President, Finance and then as Vice President, Strategy and Business Analysis of Adolor Corporation. From November 2000 to May, 2003 he served as Vice President, Finance and then as Chief Operating Officer of Opt-E-Script, Inc., a privately held personalized medicine company where Mr. Jones was responsible for all commercialization activities. Prior to that, Mr. Jones was Vice President, Sales and Marketing for Purepac Pharmaceutical Company. Mr. Jones received his M.B.A. from the University of North Carolina and a B.S. from Cornell University. Mr. Jones was appointed a director of the Company in July 2011.

Peter Clemens

Mr. Peter A. Clemens is Chief Financial Officer, Senior Vice President, Secretary of Acura Pharmaceuticals, Inc., since April 2004. Mr. Clemens was Vice President, Chief Financial Officer and Secretary from February 1998 to March 2004 and a member of the Board of Directors from June, 1998 to August, 2004. Mr. Clemens is a Certified Public Accountant and earned a Bachelor of Business Administration degree from the University of Notre Dame and a Masters of Business Administration from Indiana University.

Robert Seiser

Mr. Robert A. Seiser is Vice President, Corporate Controller and Treasurer of Acura Pharmaceuticals, Inc., since April 2004. Mr. Seiser joined the Company in March 1998 as Treasurer and Corporate Controller. Mr. Seiser is a Certified Public Accountant and earned a Bachelor of Business Administration degree from Loyola University of Chicago.

J. Bradley Rivet

Mr. J. Bradley Rivet is Vice President - Marketing of Acura Pharmaceutical Technologies, Inc., since October 2011. Prior to such time, Mr. Rivet was Vice President of Effcon Laboratories Inc. Mr. Rivet has held management positions with aaiPharma Inc. and Burroughs Welcome Co. Mr. Rivet received his Bachelor of Science degree from Louisiana State University

Albert Brzeczko

Dr. Albert W. Brzeczko is Vice President -Technical Affairs of Acura Pharmaceuticals, Inc., since February 2009. From 1999 through 2009, Dr. Brzeczko was Vice President, Global Pharma New Product Development and Pharma Technologies for International Specialty Products, Inc., a contract services group specializing in the development of technologies for the bioenhancement of poorly soluble drugs. Prior to 1999, Dr. Brzeczko held positions of increasing responsibility in pharmaceutical product development with UPM Pharmaceuticals, Banner Pharmacaps, Mylan Laboratories, and DuPont Merck. Dr. Brzeczko received a Bachelor of Science degree in biochemistry and a Ph.D. in pharmaceutical sciences from the University of Maryland.

James Emigh

Mr. James F. Emigh is Vice President - Corporate Development of Acura Pharmaceuticals, Inc., since October 2011. From April 2004 to October 2011, Mr. Emigh was Vice President of Marketing and Administration. Prior to such time, Mr. Emigh was Vice President of Sales and Marketing. Mr. Emigh joined the company in May, 1998, serving first as Executive Director of Customer Relations and then as Vice President of Operations. Mr. Emigh holds a Bachelor of Pharmacy degree from Washington State University and a Masters of Business Administration from George Mason University.

George Ross

Mr. George K. Ross is an Independent Director of Acura Pharmaceuticals, Inc., since January, 2008. Since April 2002, Mr. Ross has been a consultant to early stage businesses and a financial investor. From July 2005 through December 2010 he served as Executive Director, Foundations and Partnerships for World Vision U.S. in New York City. His business career has included senior financial officer and board member positions with both public and private companies in diverse industries. Mr. Ross was Executive Vice President and Chief Financial Officer and a board member of Tier Technologies Inc. from February 1997 to January 2000, which became a public company during this period. Mr. Ross is a Certified Public Accountant and earned a Bachelor of Arts degree from Ohio Wesleyan University and a Masters of Business Administration from Ohio State University.

William Skelly

Mr. William G. Skelly is an Independent Director of Acura Pharmaceuticals, Inc. He served as Chairman from October, 1996 through June, 2000. Since 1990, Mr. Skelly has served as Chairman, President and Chief Executive Officer of Central Biomedia, Inc. and its subsidiary SERA, Inc. From 1985 to 1990, Mr. Skelly served as President of Martec Pharmaceutical, Inc. Mr. Skelly earned a Bachelor of Arts degree from Michigan State University and a Masters of Business Administration from the University of Missouri-Kansas City.

Immanuel Thangaraj

Mr. Immanuel Thangaraj is an Independent Director of Acura Pharmaceuticals, Inc., since December, 2002. Mr. Thangaraj has been a Managing Director of Essex Woodlands Health Ventures, a venture capital firm specializing in the healthcare industry, since 1997. Prior to joining Essex Woodlands Health Ventures, he helped establish a telecommunication services company, for which he served as its CEO. Mr. Thangaraj holds a Bachelor of Arts and a Masters in Business Administration from the University of Chicago.

Bruce Wesson

Mr. Bruce F. Wesson is an Independent Director of Acura Pharmaceuticals, Inc., since March 1998. From January 1991 until June 30, 2011 Mr. Wesson was a Partner of Galen Associates, a health care venture firm, and a General Partner of Galen Partners III, L.P. Prior to January, 1991, he was Senior Vice President and Managing Director of Smith Barney, Harris Upham & Co. Inc., an investment banking firm. He serves on the Boards of Derma Sciences, Inc., and as Vice Chairman of the Board of MedAssets, Inc., each a publicly traded company. Mr. Wesson earned a Bachelor of Arts degree from Colgate University and a Masters of Business Administration from Columbia University.

Basic Compensation

Name Fiscal Year Total

Robert Jones

602,353

Peter Clemens

340,863

Robert Seiser

267,490

J. Bradley Rivet

352,988

Albert Brzeczko

452,608

James Emigh

267,490

George Ross

--

William Skelly

--

Immanuel Thangaraj

--

Bruce Wesson

--
As Of 30 Dec 2012

Options Compensation

Name Options Value

Robert Jones

0 0

Peter Clemens

1,009,375 71,156

Robert Seiser

406,225 44,633

J. Bradley Rivet

0 0

Albert Brzeczko

0 0

James Emigh

406,225 46,127

George Ross

0 0

William Skelly

0 0

Immanuel Thangaraj

0 0

Bruce Wesson

0 0
Search Stocks